COMPARE trial shows low dose DCB is “as safe and efficacious” as high dose DCB for femoropopliteal interventions


Sabine Steiner (Leipzig, Germany) talks to Vascular News about the 24-month results from the COMPARE trial – which were presented at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online) – a trial which compared a low dose paclitaxel-coated balloon (Ranger; Boston Scientific) with a high dose paclitaxel-coated balloon (IN.PACT; Medtronic) for femoropopliteal interventions.

The 12-month results presented at LINC last year indicated non-inferiority for the low dose DCB compared to the high dose balloon in relation to primary patency and safety. The 24-month data did also not show any signal for a difference between the two devices says Steiner, adding that it was “very reassuring” to see a primary patency rate of over 70% at two-years particularly as the trial involved patients with “rather long complex lesions” of up to 30 centimetres. Freedom from target lesion revascularisation was over 80% in both groups.


Please enter your comment!
Please enter your name here